US Patent Issued to LENTIGEN TECHNOLOGY, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services on May 12 for "Compositions and methods for treating cancer with anti-CD19 immunotherapy" (Maryland, Washington Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,104, issued on May 12, was assigned to LENTIGEN TECHNOLOGY INC. (Gaithersburg, Md.) and THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services (Bethesda, Md.).

"Compositions and methods for treating cancer with anti-CD19 immunotherapy" was invented by Dina Schneider (Potomac, Md.), Rimas J. Orentas (Seattle), Boro Dropulic (Ellicott City, Md.), Dimiter S. Dimitrov (Frederick, Md.) and Zhongyu Zhu (Frederick, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, ...